Dealing with the obstacles in adhering to highly active antiretroviral therapy

Journal of the Association of Nurses in AIDS Care

Volumn 17, Issue 1, 2006, Pages 18-25

  Hubbard, Minda ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

Adherence; HAART; HIV

Indexed keywords

EID: 33644782832     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jana.2005.11.002     Document Type: Article

References (30)

1. Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., De Longis, P., et al. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28, 445-449.
2. Ammassari, A., Trotta, M. P., Murri, R., Castelli, F., Narciso, P., Noto, P., et al. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl. 3), S123-S127.
3. Briggs, J. M., & Drabek, C. A. (2001). Metabolic complications of HIV and AIDS. Orthopedic Nursing, 20, 41-50.
4. Cahn, P., Pantaleo, G., Gatell, J., Squires, K., Percival, L., Piliero, P., et al. (2002, May). Atazanavir: A once-daily protease inhibitor with a superior lipid profile. Paper presented at the XIVth World Congress of Cardiology; Sydney, Australia.
5. Chesney, M. (2003). Adherence to HAART regimens. AIDS Patient Care and STDs, 17, 169-177.
6. Claxton, A. J., Cramer, J., & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23, 1296-1310.
7. Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., et al. (2003). Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases, 37, 613-627.
8. Flores, G. (2000). Culture and the patient-physician relationship: Achieving cultural competency in health care. The Journal of Pediatrics, 136, 14-23.
9. Gallant, J. E., Staszewski, S., Pozniak, A. L., DeJesus, E., Suleiman, J. M., Miller, M. D., et al. (2004). Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. Journal of the American Medical Association, 292, 191-201.
10. Gillett, J., Pawluch, D., & Cain, R. (2002). How people with HIV/AIDS manage and assess their use of complementary therapies: A qualitative analysis. Journal of the Association of Nurses in AIDS Care, 13, 17-27.
11. Graney, M. J., Bunting, S. M., & Russell, C. K. (2003). HIV/AIDS medication adherence factors: Inner-city clinic patients' self-reports. Journal of the Tennessee Medical Association, 96, 73-78.
12. Gross, R., Bilker, W. B., Friedman, H. M., Coyne, J. C., & Strom, B. L. (2002). Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS, 16, 1835-1837.
13. Haile, B. L., Landrum, P. A., Kotarba, J. A., & Trimble, D. (2002). Inner strength among HIV-infected women: Nurses can make a difference. Journal of the Association of Nurses in AIDS Care, 13, 74-80.
14. Ickovics, J. R., Cameron, A., Zackin, R., Bassett, R., Chesney, M., Johnson, V. A., et al. (2002). Consequences and determinants of adherence to antiretroviral medication: Results from Adult AIDS Clinical Trials Group protocol 370. Antiviral Therapy, 7, 185-193.
15. Ka'opua, L. S., & Mueller, C. W. (2004). Treatment adherence among Native Hawaiians living with HIV. Social Work, 49, 55-63.
16. Kirton, C. A. (2001). Promoting healthy behaviors in HIV primary care. Nurse Practitioner Forum, 12, 223-232.
17. Loughlin, L., & Jensen, H. (2000). Patient adherence to medication for HIV. Professional Nurse, 16, 897-901.
18. Melbourne, K. M. (1999). The impact of religion on adherence with antiretrovirais. Journal of the Association of Nurses in AIDS Care, 10, 99-100.
19. Moyle, G. (2002). Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens. AIDS Patient Care and STDs, 16, 585-597.
20. Murphy, D. A., Roberts, K. J., Hoffman, D., Molina, A., & Lu, M. C. (2003). Barriers and successful strategies to antiretroviral adherence among HIV-infected monolingual Spanish-speaking patients. AIDS Care, 15, 217-230.
21. Panel on Clinical Practices for Treatment of HIV Infection (2004). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [updated March 23, 2004]. Retrieved September 17, 2004, from http://aidsinfo.nih.gov/guidelines/adult/AA_032304.pdf
22. Parsons, J. T., Huszti, H. C., Crudder, S. O., Rich, L., & Mendoza, J. (2000). Maintenance of safer sexual behaviours: Evaluation of a theory-based intervention for HIV seropositive men with haemophilia and their female partners. Haemophilia, 6, 181-190.
23. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
24. Piliero, P., Cahn, P., Pantaleo, G., Gatell, J. M., Squires, K., Percival, L., et al. (2002, February). Atazanavir: A once-daily protease inhibitor with a superior lipid profile: results of clinical trials beyond week 48 [poster 706-T]. Poster presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle. Retrieved March 25, 2004, from http://www.retroconference.org/2002/Abstract/13827.htm
25. Prescribing information: Viread (tenofovir disoproxil fumarate). (2003). In Physicians' Desk Reference (pp. 1425-1428). Montvale, NJ: Medical Economics, Inc.
26. Prochaska, J. O., Redding, C. A., Harlow, L. L., Rossi, J. S., & Velicer, W. F. (1994). The transtheoretical model of change and HIV prevention: A review. Health Education Quarterly, 21, 471-486.
27. Trotta, M. P., Ammassari, A., Melzi, S., Zaccarelli, M., Ladisa, N., Sighinolfi, L., et al. (2002). Treatment-related factors and highly active antiretroviral therapy adherence. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl. 3), S128-S131.
28. Tucker, J. S., Burnam, M. A., Sherbourne, C. D., Kung, F. Y., & Gifford, A. L. (2003). Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medicine, 114, 573-580.
29. Williams, A. B. (1999). Adherence to highly active antiretroviral therapy. Nursing Clinics of North America, 34, 113-129.
30. Williams, A. B. (2001). Adherence to HIV regimens: ten vital lessons. American Journal of Nursing, 101, 37-43.